PSK Pharma, a biopharmaceutical company and part of Rus Biopharm Group, and a resident of the Dubna Special Economic Zone (SEZ), has announced a major strategic milestone: its portfolio of registered medicinal products has reached 100. This achievement represents a significant step forward for Russia’s domestic pharmaceutical industry and highlights the company’s contribution to advancing import substitution and strengthening national pharmaceutical independence.
Expanding Across Therapeutic Areas: From Pulmonology to Biotechnology
Over the past six years, PSK Pharma has developed a full-cycle manufacturing platform and expanded its presence across a wide range of therapeutic areas.
The company’s 100th registered product is an inhalation therapy, further reinforcing its strong position in pulmonology. The portfolio currently includes 25 products for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Evgenia Shapiro, General Director of PSK Pharma, commented:
«Reaching 100 registered products is more than a symbolic milestone - it reflects millions of patients gaining access to high-quality, reliable therapies. As a responsible Russian pharmaceutical manufacturer, we are committed to supporting the country’s pharmaceutical sovereignty. Our focus on full-cycle production, including the localization of active pharmaceutical ingredients, enables us to ensure a stable and uninterrupted supply of medicines regardless of external challenges.
We see the evolving needs of the market and continue to respond to them by developing complex generics and biosimilars, while strengthening our scientific expertise and expanding our manufacturing capabilities».
PSK Pharma invests over 1 billion RUB annually in modernization and capacity expansion. Construction of a third manufacturing facility, with a total area of 22,000 square meters, is currently nearing completion at the Dubna SEZ. The new site will include:
- an advanced production complex
- a fully automated facility for manufacturing empty hard gelatin capsules
- looking ahead, the company plans to build two additional facilities, significantly increasing production capacity and accelerating the introduction of new products to the market
Portfolio Development Milestones
2019 — Launch of a full-cycle manufacturing facility in the Dubna SEZ, establishing the company’s production base.
2020 — Introduction of the first in-house antibiotics, marking entry into antibacterial therapies.
2021 — Launch of the biotechnology segment, including production of etanercept for the treatment of rheumatoid diseases.
2023 — Recognition by the Russian Union of Industrialists and Entrepreneurs (RSPP) for leadership in import substitution. Several products were localized in Russia for the first time, with PSK Pharma remaining the sole domestic manufacturer.
2024–2025 — Major portfolio expansion into advanced therapeutic areas:
- Development of polypeptide-based drugs, including semaglutide and tirzepatide
- Expansion of the HIV portfolio to seven products
- Entry into the segment of specialized pediatric medicines
- Strengthening biotechnology capabilities for in-house API synthesis
2026 - 100 registered medicinal products. PSK Pharma is currently ranked among the top three pharmaceutical companies in Russia by the number of clinical trial approvals.